Chloride voltage-gated channel 3 (CLCN3)

Chloride voltage-gated channel 3 (CLCN3) is a member of the ClC family of chloride channels and transporters that plays a pivotal role in the pathophysiology of malignant gliomas [1, 2]. While typically localized to endosomal membranes in healthy cells to facilitate organelle acidification, CLCN3 is significantly upregulated and redistributed to the plasma membrane in glioma cells [2, 4]. In this context, it functions as a volume-regulated anion channel that allows for the rapid efflux of chloride ions and water, enabling the cell to undergo the hydrodynamic volume changes necessary for migration and invasion through the brain's tight extracellular spaces [2, 4]. CLCN3 often forms macromolecular complexes with other proteins, such as Matrix Metalloproteinase-2 (MMP-2) and Annexin A2, to coordinate extracellular matrix degradation with cell shrinkage [3, 4]. Therapeutic strategies, most notably the use of the scorpion venom-derived peptide chlorotoxin (TM-601), aim to inhibit these channels or their associated complexes to arrest tumor spread [3, 5]. Consequently, CLCN3 is considered a high-priority target for both imaging and targeted therapy in glioblastoma multiforme [4, 5].

Other names

CLC-3ClC-3Chloride channel protein 3CLCN3Glioma-associated chloride channel

Inhibition of chloride ion efflux through the CLCN3 channel, which prevents the hydrodynamic cell volume reduction required for glioma cells to invade narrow brain parenchyma spaces [2, 4].